Upstream Bio (UPB) Retained Earnings (2023 - 2026)
Upstream Bio (UPB) posted quarterly Retained Earnings of -$374.8 million for Q1 2026, down 156.51% year-over-year from $663.2 million in Q1 2025, and down 70819.62% quarter-over-quarter from $530000.0 in Q4 2025.
Upstream Bio (UPB) Retained Earnings (2023 - 2026) Analysis & Trends
Upstream Bio's Retained Earnings history runs 4 years deep, the most recent figure standing at -$374.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 156.51% year-over-year to -$374.8 million; the TTM figure through Mar 2026 stood at -$374.8 million (down 156.51% YoY), while the FY2025 annual figure was $530000.0, down 99.92% from the prior year.
- Retained Earnings for Q1 2026 stood at -$374.8 million, down from $530000.0 in the prior quarter.
- The five-year high for Retained Earnings was $666.4 million in Q2 2025, with the low at -$374.8 million in Q1 2026.
- The 4-year median for Retained Earnings is $6.8 million (2023), against an average of $203.8 million.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 13594.11% in 2024, then plunged 156.51% in 2026.
- Upstream Bio's Retained Earnings stood at $4.8 million in 2023, then soared by 13594.11% to $660.6 million in 2024, then slumped by 99.92% to $530000.0 in 2025, then tumbled by 70819.62% to -$374.8 million in 2026.
- Business Quant data shows UPB's Retained Earnings at -$374.8 million in Q1 2026, $530000.0 in Q4 2025, and $493000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 685.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 685.54 Mn |
| Mar 31, 2026 | -374.81 Mn |
| Dec 31, 2025 | 530,000.00 |
| Sep 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 666.45 Mn |
| Mar 31, 2025 | 663.24 Mn |
| Dec 31, 2024 | 660.60 Mn |
| Sep 30, 2024 | 8.87 Mn |
| Dec 31, 2023 | 4.82 Mn |